Other babesiosis
ICD-10 B60.09 is a billable code used to indicate a diagnosis of other babesiosis.
Babesiosis is a malaria-like parasitic disease caused by protozoa of the genus Babesia, primarily transmitted through the bite of infected Ixodes ticks. The condition is characterized by symptoms such as fever, chills, sweats, headache, and myalgia, which can range from mild to severe. In some cases, it can lead to complications such as hemolytic anemia, thrombocytopenia, and multi-organ failure, particularly in immunocompromised individuals or those without a spleen. Diagnosis is typically confirmed through blood smear microscopy or serological tests detecting Babesia antibodies. Treatment usually involves the use of antimalarial medications such as atovaquone combined with azithromycin or clindamycin combined with quinine. The disease is more prevalent in certain geographic regions, particularly in the northeastern and upper midwestern United States, and is considered a significant public health concern due to its potential for severe illness and the increasing incidence of reported cases.
Detailed patient history, laboratory results, and treatment plans.
Patients presenting with fever and recent travel to endemic areas.
Consideration of co-infections and immunocompromised status.
Thorough documentation of symptoms, exposure history, and initial treatment response.
Patients with flu-like symptoms and potential tick exposure.
Early recognition and referral to specialists if severe symptoms develop.
Used when testing for Babesia in patients with suspected infection.
Document the reason for testing and any relevant clinical findings.
Infectious disease specialists may require additional details on patient history.
Common symptoms include fever, chills, sweats, headache, and myalgia. Severe cases may lead to hemolytic anemia and multi-organ failure.
Diagnosis is typically confirmed through blood smear microscopy or serological tests that detect antibodies against Babesia.
Treatment usually involves antimalarial medications such as atovaquone combined with azithromycin or clindamycin combined with quinine.
Yes, babesiosis is considered a reportable disease in many jurisdictions due to its public health implications.
